34.19
-1.16 (-3.28%)
| Previous Close | 35.35 |
| Open | 35.39 |
| Volume | 386,480 |
| Avg. Volume (3M) | 800,312 |
| Market Cap | 1,949,862,400 |
| Price / Earnings (TTM) | 2.93 |
| Price / Sales | 102.02 |
| Price / Book | 2.06 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Profit Margin | 2,051.38% |
| Operating Margin (TTM) | -1,146.93% |
| Diluted EPS (TTM) | 11.66 |
| Quarterly Revenue Growth (YOY) | 21.20% |
| Total Debt/Equity (MRQ) | 3.74% |
| Current Ratio (MRQ) | 8.99 |
| Operating Cash Flow (TTM) | -329.16 M |
| Levered Free Cash Flow (TTM) | -157.06 M |
| Return on Assets (TTM) | -18.17% |
| Return on Equity (TTM) | 53.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Agios Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.20 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.51% |
| % Held by Institutions | 106.85% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 30 Sep 2024 | 5,660,866 |
| Armistice Capital, Llc | 30 Sep 2024 | 2,207,070 |
| Erste Asset Management Gmbh | 30 Sep 2024 | 2,184,900 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (Scotiabank, 119.36%) | Buy |
| Median | 56.50 (65.25%) | |
| Low | 51.00 (Raymond James, 49.17%) | Buy |
| Average | 59.75 (74.76%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 45.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 10 Dec 2024 | 57.00 (66.72%) | Buy | 46.02 |
| 01 Nov 2024 | 55.00 (60.87%) | Buy | 44.87 | |
| Scotiabank | 09 Dec 2024 | 75.00 (119.36%) | Buy | 48.64 |
| 01 Nov 2024 | 53.00 (55.02%) | Buy | 44.87 | |
| Raymond James | 10 Oct 2024 | 51.00 (49.17%) | Buy | 41.82 |
| Leerink Partners | 27 Sep 2024 | 56.00 (63.79%) | Hold | 45.61 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Dec 2024 | Announcement | European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease |
| 08 Dec 2024 | Announcement | Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat |
| 05 Nov 2024 | Announcement | Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition |
| 31 Oct 2024 | Announcement | Agios Reports Business Highlights and Third Quarter 2024 Financial Results |
| 23 Oct 2024 | Announcement | Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease |
| 17 Oct 2024 | Announcement | Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |